SCHEMBL16264384

SCHEMBL16264384

CC(=O)Nc1cc(C(=O)Nc2sccc2C(=O)Nc2ccc(Cl)cc2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
MAPK1 P28482 1/20 0.44
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
TYK2 P29597 1/20 0.44
AGER Q15109 1/20 0.44
MAPT P10636 3/20 0.43
GSK3B P49841 2/20 0.43
PTGS2 P35354 1/20 0.43
HIF1A Q16665 1/20 0.42
HDAC8 Q9BY41 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16264394 0.85 MAPK10 (0.57) POLBMEN1KMT2ANPC1RAB9A
SCHEMBL16264498 0.81 PIK3C3 (0.49) POLBMEN1KMT2ANPC1RAB9A
SCHEMBL16264472 0.78 CYP2C9 (0.58) NPC1RAB9ASMN1; SMN2KDM4EMAPK10
SCHEMBL16264389 0.76 PIK3C3 (0.52) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL16264397 0.76 MEN1 (0.50) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL17905920 0.75 PIK3C3 (0.47) JAK2JAK1TYK2AGER
SCHEMBL16264405 0.75 KMT2A (0.62) MEN1KMT2AMAPTGSK3BKDM4E
SCHEMBL16264408 0.73 CYP2C9 (0.42) NPC1RAB9AGSK3BSMN1; SMN2KDM4E
SCHEMBL16264534 0.71 ALDH1A1 (0.50) POLBMEN1KMT2ANPC1RAB9A
SCHEMBL16264497 0.71 FLT3 (0.41) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160194299-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-07-07 US disclosed
US-20160194299-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-07-07 US disclosed
WO-2014190199-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194299-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS FNTB, PGLS, EP300 POLB 863/4885MEN1 3943/4885KMT2A 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.